Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2024-04-24), Bio-Rad Laboratories's Intrinsic Value: Projected FCF is $335.36. The stock price of Bio-Rad Laboratories is $279.91. Therefore, Bio-Rad Laboratories's Price-to-Intrinsic-Value-Projected-FCF of today is 0.8.
The historical rank and industry rank for Bio-Rad Laboratories's Intrinsic Value: Projected FCF or its related term are showing as below:
BIO.B'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.83 Med: 1.72 Max: 2.31
Current: 0.83
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Bio-Rad Laboratories was 2.31. The lowest was 0.83. And the median was 1.72.
BIO.B's Price-to-Projected-FCF is ranked better than 78.84% of 345
companies
in the Medical Devices & Instruments industry
Industry Median: 1.68
vs BIO.B: 0.83
Bio-Rad Laboratories Intrinsic Value: Projected FCF Historical Data
The historical data trend for Bio-Rad Laboratories's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Bio-Rad Laboratories's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Rad Laboratories Price-to-Projected-FCF Distribution
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Bio-Rad Laboratories's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Bio-Rad Laboratories's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
279.91
/
341.79288574698
=
0.82
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Rad Laboratories Intrinsic Value: Projected FCF Related Terms
Thank you for viewing the detailed overview of Bio-Rad Laboratories's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Bio-Rad Laboratories (Bio-Rad Laboratories) Business Description
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas, Europe and Africa , and Asia-Pacific. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BIO.B has been successfully added to your 